BACKGROUND: A combination of @entity750 receptor ( @entity750 receptor type 3) antagonists, NK-1 receptor antagonist, and @entity479 improves the complete response (CR) of chemotherapy-induced @entity1209 (CINV) in @entity5 @entity1 . @entity16243 's efficacy in this triple combination regimen has not been investigated. This prospective, multicenter, single-blind, randomized, phase III study compares a combination of @entity16243 , aprepitant, and @entity619 ( @entity15817 ) with a combination of @entity3974 , aprepitant, and @entity619 (OAD) to prove the noninferiority of @entity15817 in controlling highly emetogenic CINV. METHODS: Aprepitant and @entity619 were orally administered for both arms. @entity16243 and @entity3974 were intravenously given to the @entity15817 and OAD groups. The primary endpoint was no @entity391 and retching and no need for rescue medication during the acute period (day 1); the noninferiority margin was -15%. RESULTS: A total of 299 modified intention-to-treat @entity5 @entity1 who received @entity15817 (144 @entity1 ) and OAD (155 @entity1 ) were eligible for the efficacy analysis. The CR rates of @entity15817 versus OAD were 97.2% versus 93.6% during the acute period, 77.8% versus 73.6% during the delayed period (day 2-5), and 77.1% versus 71.6% during the overall period. Furthermore, @entity15817 was noninferior to OAD in subgroups stratified by age, @entity5 type, chemotherapeutic agents, and schedule. Repeated measures analysis showed that in male @entity1 , @entity15817 was superior to OAD. Profiles of adverse events were similar in both groups. CONCLUSION: @entity15817 is as effective and tolerable as OAD for CINV prevention in @entity1 receiving highly emetogenic chemotherapy. @entity16243 could be considered one of the best partners for aprepitant. IMPLICATIONS FOR PRACTICE: This is the first prospective, multicenter, randomized phase III study to show that @entity16243 , a new @entity750 receptor type 3 antagonist, is as effective and tolerable as @entity3974 when administered in combination with aprepitant and @entity619 for the prevention of chemotherapy-induced @entity1209 in @entity1 receiving highly emetogenic chemotherapy.

@entity16243 Versus XXXX in Combination With Aprepitant and @entity619 for the Prevention of Highly Emetogenic Chemotherapy-Induced @entity1209 : A Multicenter, Randomized Phase III Trial, KCSG PC10-21.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity16243 :: ('MESH:C071315', 'Chemical') :: ['Ramosetron', 'ramosetron'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity15817 :: ('6236', 'Gene') :: ['RAD'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['5-hydroxytryptamine', 'serotonin'] @entity479 :: ('D013256', 'Chemical') :: ['steroid'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']
@entity3974 :: (MESH:D017294,Chemical) :: ['Ondansetron']
